Davita Inc vs iShares Semiconductor ETF — how do they compare? Davita Inc trades at $178.01 (market cap $11.29B), while iShares Semiconductor ETF trades at $561.82 (market cap $48.19B). The key difference: iShares Semiconductor ETF is far larger — about 4.3× Davita Inc's market cap, and iShares Semiconductor ETF is trading nearer its 52-week high, Davita Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Davita Inc for 113 Days and iShares Semiconductor ETF for 46 Days on average.
| DVA | SOXX | |
|---|---|---|
Market Cap | $11.29B | $48.19B |
Volume | 582,204 | 10,257,578 |
Sector | Health | Sector/Thematic |
52-Week High | $240.96 | $655.01 |
52-Week Low | $103.87 | $268.10 |
Typical Hold Time | 113 Days | 46 Days |
Enterprise Value | $24.01B | — |
Signals from Pluang's Aura AI — not financial advice
DaVita (DVA) trades at $176.78, down 2.01% today, with a bearish technical signal and neutral oscillators. The company shows strong earnings beats in recent quarters with Q2 2026 EPS of $4.02 beating expectations of $3.88. Revenue growth continues from $13.64B in 2025 to projected $14.0B in 2026, though net margins have fluctuated. Recent partnership expansion with Humana for value-based kidney care represents significant business development.
DVA presents a mixed outlook with 43% analyst buy ratings and a $235.67 price target suggesting 33% upside. However, high debt levels (65.55% debt-to-asset ratio) and regulatory risks in healthcare weigh on fundamentals. The stock's current valuation at P/E 15 and P/S 0.88 appears reasonable relative to earnings growth potential, making it attractive for value investors despite near-term bearish technicals.
SOXX trades at $582.94, down 1.1% today but maintains a bullish technical stance with strong moving average support. The semiconductor ETF benefits from AI-driven demand, with recent news highlighting sector gains and positive earnings momentum. However, high valuations and Michael Burry's expanded short position signal caution amid the AI boom.
Outlook remains positive due to structural AI growth, but risks include valuation concerns and sector concentration. Earnings growth supports further upside, though macroeconomic conditions and competitive pressures could temper returns. Investors should balance optimism with prudent risk management.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
DaVita is the largest provider of dialysis services in the United States, boasting market share that eclipses 35% when measured by both patients and clinics. The firm operates over 3,100 facilities worldwide, mostly in the U.S., and treats over 240,000 patients globally each year. Government payers dominate U.S. dialysis reimbursement. DaVita receives approximately 69% of U.S. sales at government (primarily Medicare) reimbursement rates, with the remaining 31% coming from commercial insurers. However, while commercial insurers represented only about 10% of the U.S. patients treated, they represent nearly all of the profits generated by DaVita in the U.S. dialysis business.
Read more on DVA →SOXX provides investors with exposure to U.S. companies that design, manufacture, and distribute semiconductors. It tracks the ICE Semiconductor Index, offering a targeted investment in the technology sector's foundational components, including firms that produce chips, related equipment, and services. SOXX is a key vehicle for investors seeking to capitalize on trends in artificial intelligence, 5G, and other technologies that rely heavily on advanced semiconductor technology.
Read more on SOXX →